HUNDREDS of women with breast cancer will gain months of extra life thanks to new NHS drug.
Patients with an incurable type of cancer called HER2-positive will be offered the drug Enhertu to slow its progression.
Around 600 women in England are expected to benefit when their cancer returns after treatment.
Trials have shown that a drug known as trastuzumab deruxtecan can halve the risk of disease progression or death in some patients within the first 18 months after taking it.
This increased the amount of time without tumor growth to an average of 9.9 months compared to 5.1 months with standard chemotherapy.
Peter Clarke, from the National Health Service of England’s Cancer Medicines Fund, said: “This cutting-edge drug will bring hope to hundreds of patients with incurable secondary breast cancer.
“This will increase the amount of time people have before their cancer gets worse and allow them to live normal, healthy lives longer.”
Breast Cancer Now Executive Director Baroness Delit Morgan said the NIH endorsement and excellence was “fantastic news.”
Trials of the drug are ongoing to see if it will benefit more patient groups.
#Hundreds #Breast #Cancer #Patients #Months #Life #NHS #Drug